Routine data from prevention of mother-to-child transmission (PMTCT) HIV testing not yet ready for HIV surveillance in Mozambique: a retrospective analysis of matched test results by unknown
RESEARCH ARTICLE Open Access
Routine data from prevention of mother-to-child
transmission (PMTCT) HIV testing not yet ready
for HIV surveillance in Mozambique: a
retrospective analysis of matched test results
Peter W Young1*, Mussagy Mahomed2, Roberta Z Horth3, Ray W Shiraishi4 and Ilesh V Jani2
Abstract
Background: Opt-out HIV testing is offered at 70% of antenatal care (ANC) clinics in Mozambique through the
prevention of mother-to-child transmission (PMTCT) program. If routine data from this program were of sufficient
quality, their heightened coverage and continuous availability could complement or even replace biannual sentinel
serosurveys that currently serve as the primary HIV surveillance system in Mozambique.
Methods: We assessed the efficacy of routine HIV testing data from prevention of mother-to-child transmission
programs for estimating the prevalence of HIV infection among pregnant women. The PMTCT program uses
sequential point-of-care rapid tests conducted on site while ANC surveillance surveys use dried blood spots tested
sequentially for HIV-1/2 antibodies at a central laboratory. We compared matched routine PMTCT and ANC
surveillance test results collected during 2007 and 2009 ANC surveillance surveys from 36 sentinel sites.
Results: After excluding 659 women without PMTCT data, including 83 who refused rapid testing, test results from
a total of 20,563 women were available. Pooling the data from both years indicated HIV prevalence from routine
PMTCT testing was 14.4% versus 15.2% from surveillance testing (relative difference -5.1%; absolute difference
-0.78%). Positive percent agreement (PPA) of PMTCT versus surveillance tests was 88.5% (95% Confidence Interval
[CI]: 85.7-91.3%), with 19 sites having PPA below 90%; Negative percent agreement (NPA) was 98.9% (CI: 98.5-
99.2%). No significant difference was found among three regions (North, Center and South), however both PPA and
NPA were significantly higher in 2009 than 2007 (p < 0.05).
Conclusions: We found low PPA of PMTCT test results compared to surveillance data which is indicative either of
testing errors or data reporting problems. Nonetheless, PPA improved significantly from 2007 to 2009, a possible
positive trend that should be investigated further. Although use of PMTCT test results would not dramatically
change HIV prevalence estimates among pregnant women, the impact of site-level differences on surveillance
models should be evaluated before these data are used to replace or complement ANC surveillance surveys.
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Background
Mozambique has a generalized HIV epidemic with adult
prevalence estimated at 11.5% [1]. Surveillance data
show the prevalence stabilizing at the national level, but
with distinct regional levels and trends [2].
Mozambique began using serosurveys in ANC clinics
for HIV surveillance in 1988. Antenatal care HIV
surveillance was restricted to one site in the capital city
until the end of the civil war in 1992, but expanded
rapidly in the late nineties, reaching 36 sites located in
both urban and rural areas and in all 11 provinces by
2001. These surveys are currently conducted every two
years and as of 2007 have been based on centralized
Enzyme-Linked Immunosorbent Assay (ELISA) testing
of dried blood spot (DBS) specimens for presence of
HIV antibodies prepared from leftover blood from
routine syphilis tests. The national health service began
offering rapid HIV tests at ANC clinics as part of the
Mozambican national prevention of mother-to-child
transmission (PMTCT) program in 2003. With the
expansion of HIV testing in PMTCT program settings
in Mozambique, 70% of all ANC sites in Mozambique
provided opt-out rapid HIV testing with same day
return of results during ANC visits; as of 2007 all 36
sentinel surveillance sites have provided this service.
Women who attend ANC are generally representative
of all pregnant women in Mozambique due to high
(86%) ANC coverage [3]. If routine HIV test data from
the PMTCT program can provide reliable estimates of
HIV prevalence in pregnant women, these data could
supplement or replace traditional ANC serosurveys, at
lower cost and potentially with greater frequency, cover-
age and precision.
Before relying on such data for surveillance purposes,
it is first necessary to evaluate: 1) the availability of rou-
tine PMTCT program data; 2) differences in test results
between the PMTCT and ANC surveillance programs;
and 3) any bias that may be introduced by differences in
uptake, data quality, and testing procedures between
these data sources. In this paper we examine differences
in test results and test uptake between the PMTCT and
ANC surveillance programs in 2007 and 2009.
There are well-established procedures for evaluat-
ing new diagnostic methods against a gold standard
diagnostic method and reporting the results from
such evaluations [4,5]. We felt that in this study
discrepant results could be due to differences in viral
detection due to differing window periods, errors in
rapid testing, centralized ELISA testing, or specimen
handling, or a combination of reasons. Therefore, we
treated centralized ELISAs as a non-reference stand-
ard, as has been recommended in the case of evalu-
ating a diagnostic system when a gold standard is
not available [6].
We used existing data collected through the HIV sur-
veillance system to evaluate the reliability of PMTCT and
ANC surveillance test results and to identify potential
biases due to refusals and other causes of missing HIV test
results. Based on this, we further consider the potential
impact on HIV prevalence estimates if routine PMTCT
data were used instead of traditional surveillance data
from ANC surveys. Since the surveillance system itself
was used to collect the data reported in this evaluation,
questions of availability and quality of routine PMTCT
data in Mozambique, though important considerations,
are not evaluated here, but are being assessed through a
separate ongoing study.
Methods
ANC surveillance procedures in Mozambique are based
on UNAIDS/WHO guidelines [7]. In 2007 Mozambique
adopted an informed consent process for ANC surveil-
lance. After participation in a group discussion with the
ANC nurse, during their first ANC visit women are
asked for verbal informed consent for use of leftover
blood from syphilis testing to prepare DBS specimens
with linked demographic data for HIV surveillance
purposes. Those who refuse to give blood for syphilis
testing are ineligible for the survey, although those
refusing syphilis testing or ANC surveillance could still
participate in PMTCT HIV testing. Similarly, those who
refuse a PMTCT HIV test are still encouraged to par-
ticipate in ANC surveillance. ANC surveillance testing
is anonymous and surveillance test results are not
returned to participants. Although women had the
opportunity to refuse ANC surveillance, uptake was
98.9% in both 2007 and 2009 [2,8].
The PMTCT program is integrated into ANC in
Mozambique. Provider-initiated testing and counseling
is performed by the maternal-child health nurse during
the first ANC visit and is based on the national HIV
diagnostic testing algorithm [4,9]. Women are first
screened with Determine HIV-1/2 (Abbott Laboratories,
Abbott Park, Illinois, USA, sensitivity 100.0% [CI: 95.5-
100.0%], specificity 99.4% [CI: 96.7-100.0%] [10]); those
that test positive are confirmed with Uni-Gold HIV
(Trinity Biotech, Dublin, Ireland, sensitivity 100.0%
[CI: 95.5-100.0%], specificity 100.0% [CI: 97.9-100.0%]
[10]); discordant results are considered indeterminate
and clients are asked to return after one month for
repeat testing. During the surveillance round a single
venous blood draw using vacuum tubes is used to pre-
pare rapid tests, a rapid plasma reagin (RPR) syphilis
test, and for those who consent to participate, DBS
specimens for centralized ANC surveillance testing.
During the ANC surveillance survey, nurses docu-
mented in the ANC surveillance register whether the cli-
ent consented to participate in ANC surveillance, whether
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the client had an HIV test conducted as part of the
PMTCT program, and whether the client had ever had a
previous HIV positive test result. Results from rapid HIV
tests conducted by the PMTCT program were recorded
along with demographic data and a unique code. If the
client consented to ANC surveillance, the nurse also
labeled filter paper cards with the same unique code and
prepared DBS specimens which were later sent to the
National Immunology Reference Lab in Maputo for
centralized antibody testing with ELISA. ELISA testing
included a Vironostika HIV Uniform II plus O (bioMérieux
bv, Netherlands, sensitivity 100.0% [CI: 99.6-100.0%],
specificity 100.0% [CI: 99.7-100.0%]) screening test
followed by confirmation of positive specimens with
Murex HIV 1-2-O (Abbott Laboratories, UK, sensitivity
100% [CI: 99.97-100%], specificity 99.91% [CI: 99.82-
99.96%]). Discordant results were considered HIV-negative.
As results from repeat testing of women with indeterminate
results were not available for analysis, in this analysis
indeterminate PMTCT rapid test results were recoded as
HIV-negative for comparison with ELISA test results for
consistency.
Records were limited to the first 300 ANC surveil-
lance participants per sentinel site per year to ensure
similar weighting across sites. Test results were
matched by unique code, pooled across the 36 surveil-
lance sites and surveys from the two years (2007 and
2009) included in this analysis, and then disaggregated
by region and year for further analysis. It was not
possible to remove women who may have participated
in both the 2007 and 2009 surveys. Although pooled
prevalence was used for this study, the median of
the site-level HIV prevalence is also reported for
consistency with WHO recommendations [7].
Data were analyzed retrospectively to assess consistency
of test results between routine PMTCT and ANC
surveillance data, with the surveillance algorithm using
second generation antibody tests and no tie-breaker for
resolving indeterminate results. Thus, the final ELISA
result serves as a non-reference standard which may
itself, in some cases, produce an erroneous diagnosis. In
such cases, the matched rapid test results may either
also be false positive or false negative (leading to high
agreement but low sensitivity and specificity) or may
represent the correct diagnosis (leading to lower agreement
but high sensitivity and specificity). Positive percent agree-
ment (PPA) and negative percent agreement (NPA) were
calculated to assess the level of agreement between the
rapid test results under evaluation and the non-reference
standard ELISA result. The prevalence ratio between
refusers and non-refusers of PMTCT testing and the
percent bias due to refusals that would be introduced if
ANC surveillance were based on routine PMTCT tests
instead of ELISA test results were also calculated.
Analyses were performed with R Version 2.13.1 [11],
including analyses of complex samples which were done
using the R survey module [12]. Comparisons of PPA and
NPA were done using SAS Software Version 9.2 (SAS
Institute Inc, Cary, NC) using the Rao-Scott chi-square
test implemented in PROC SURVEYFREQ. Each surveil-
lance site was treated as a separate cluster and all women
were given equal weight. Results with a p-value < 0.05
were considered significant.
The ANC surveillance protocol, including the com-
parison of ANC surveillance data with routine PMTCT
test results, was approved by the Mozambican Bioethics
Committee and the U.S. Centers for Disease Control
and Prevention (CDC).
Results
After excluding 659 women who did not have PMTCT
rapid test results, including 83 due to refusal to have a
rapid test performed, 20,563 women had HIV rapid and
ELISA test results available for analysis in the combined
two-year test period (Table 1). Positive percent agreement
of rapid tests versus ELISA was 88.5% (95% Confidence
Interval [CI]: 85.7-91.3%). At the regional level, PPA was
83.4% (CI: 77.9-88.9%) in the south, 89.7% (CI: 85.4-
94.0%) in the center, and 89.2% (CI: 85.0-93.4%) in the
north of the country. The median PPA across all 36
surveillance sites was 88.8% (Interquartile Range [IQR]:
83.1-93.0%, minimum 63.8%, maximum 100.0%); Nine-
teen sites had a PPA below 90% (See Additional file 1:
Table S1, which shows site-level measures of agreement).
However, when analyzed by survey year, the pooled PPA
was found to increase from 86.5% (CI: 82.5-90.4%) in 2007
to 90.6% (CI: 87.6-93.5%) in 2009 (p = 0.040). Negative
percent agreement for both years combined was 98.9%
(CI: 98.5-99.2%), and above 98% in all three regions and in
both years. The median NPA across the surveillance sites
was 99.1% (IQR: 98.6-99.5%). No significant difference
was found among the three regions for either PPA
(p = 0.203) or NPA (p = 0.210), but as was the case with
PPA, NPA was significantly higher in 2009 than in 2007
(p = 0.028) (Table 2).
The median of the 36 HIV site-level prevalence
estimates calculated from routine PMTCT results was
13.5% (IQR 7.0-21.4%), while the median of the 36 HIV
site-level prevalence estimates calculated from surveil-
lance data was 14.4% (IQR 8.2-21.8%). When HIV test
results were pooled across sites, HIV prevalence from
routine PMTCT data was 14.4% versus 15.2% from
surveillance data. In absolute terms, HIV prevalence was
0.78 percentage points lower when measured from
routine PMTCT rapid tests, representing a 5.1% relative
decrease in prevalence compared with the results of
ELISA tests performed on matched specimens from the
same participants (Table 3). The relative difference in
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HIV prevalence at the level of each surveillance site
varied from 0-22.2%, after excluding one outlier of 100%,
and the absolute difference varied from 0-4.3 percentage
points (See Additional file 2: Table S2, which shows site-
level difference in prevalence between routine PMTCT
and ANC surveillance test results). As a surveillance sys-
tem based on PMTCT test results would likely classify
previously-diagnosed women as HIV-positive, we also
re-calculated the PMTCT prevalence estimate including
known positives. Given the small number of women
who refused a PMTCT test due to known HIV status
(n = 65, Table 1) the potential impact of including these
women in the HIV prevalence estimate derived from
routine PMTCT data was minimal (14.5% or 0.77 per-
centage points lower versus 0.78 percentage points lower
when excluded, calculations not shown). Two of these
65 “known positives” had a negative ELISA test result.
Pooled HIV prevalence based on ANC surveillance
among those who refused PMTCT testing for reasons
other than a previous diagnosis (n = 83) was 10.8% (CI:
6.6-15.0%), compared with 15.5% (CI: 12.8-18.2%) among
non-refusers. Among those women missing PMTCT
results for other reasons (n = 511), prevalence was 18.4%
(CI: 12.5-24.3%). The ratio of HIV prevalence among
refusers compared with non-refusers was 0.70, while the
ratio of HIV prevalence among women missing routine
PMTCT results for reasons other than refusal with those
not missing results was 1.19. The percent bias that would
be introduced by excluding those who refused routine
PMTCT testing from the sample was 0.12%, while the
percent bias that would be introduced by excluding those
who had missing routine PMTCT test results for reasons
other than refusal from the sample was -0.47% (Table 4).
Discussion
There is increasing interest in the use of routine PMTCT
data to supplement or replace ANC surveillance surveys
[13]. Countries and agencies such as WHO and the U.S.
Centers for Disease Control and Prevention have begun
looking at the availability of routine PMTCT data, their
quality, differences in populations covered by PMTCT
testing and ANC surveillance, as well as issues related to
differences in diagnostics. Finally, investigators have
calculated the likely impact of these differences on HIV
prevalence estimates [14-17]. In spite of varying levels of
availability and quality of routine PMTCT data, and less-
than-universal uptake of PMTCT, prevalence estimates
are often robust at the national level yet variable at the site
level and investigators have generally been cautious about
recommending a switch to routine data sources for ANC
surveillance purposes [13]. This may be due in part to the
Table 1 Availability of and differences between routine PMTCT and ANC surveillance test results in Mozambique
n
Availability of routine PMTCT HIV status for specimens with ANC surveillance results Comparison between
routine PMTCT (R) and
ANC surveillance (S)





surveillance testsTotal Refused PMTCTHIV test
Prior positive
HIV test
Other reason1 R-S+ R+S+ R+S- R-S-
Region
South 5891 162 16 23 123 2.75 5729 128 1058 71 4472
Center 8895 220 2 39 179 2.47 8675 147 1278 69 7181
North 6436 277 65 3 209 4.30 6159 84 422 59 5594
Year
2007 10588 224 82 9 133 2.12 10364 213 1359 125 8667
2009 10634 435 1 56 378 4.09 10199 146 1399 74 8580
Total 21222 659 83 65 511 3.11 20563 359 2758 199 17247
Notes:
1. Refers to missing data in the ANC surveillance register with no documented refusal or prior positive HIV test.
Table 2 Percent agreement of routine PMTCT HIV status








South 5729 83.4 (77.9-88.9) 99.0 (98.5-99.4)
Center 8675 89.7 (85.4-94.0) 99.0 (98.6-99.5)
North 6159 89.2 (85.0-93.4) 98.4 (97.7-99.1)
Year
2007 10364 86.5 (82.5-90.4) 98.6 (98.1-99.0)
2009 10199 90.6 (87.6-93.5) 99.1 (98.8-99.5)
Total 20563 88.5 (85.7-91.3) 98.9 (98.5-99.2)
Median (IQR) 36 88.8 (83.1-93.0) 99.1 (98.6-99.5)
Notes:
1. Positive percent agreement calculated as R+S+/(R+S+ and R-S+) where R
+/R- refers to routine PMTCT HIV status and S+/S- refers to ANC surveillance
HIV status.
2. Negative percent agreement calculated as R-S-/(R+S- and R-S-).
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use in many countries with generalized HIV epidemics of
modeling tools such as Spectrum which rely on site-level
HIV prevalence data to estimate national HIV prevalence
trends [18] and which may be sensitive to differences in
site-level estimates.
Switching to routine sources for ANC surveillance
purposes represents a potential long term cost savings
for national HIV programs. Such savings will not only
depend on system design but also on the cost of improv-
ing routine PMTCT HIV testing and data collection
systems to the point where they can be used for surveil-
lance. The degree to which such improvements will
strengthen the health system will depend on whether
they will affect the entire program or just a limited
number of sentinel sites.
Many evaluations of the suitability of routine HIV testing
for surveillance purposes have focused on bias due to
refusals, while few, if any, have looked at differences that
may arise due to testing methods. This evaluation
focused specifically on issues of consistency of test
results in a matched sample of PMTCT rapid test and
centralized ELISA test results and the impact that
differences in test results and uptake of rapid PMTCT
HIV testing would have on prevalence estimates. Studies
Table 3 Differences in HIV prevalence between routine PMTCT HIV status and ANC surveillance tests in Mozambique
n
Prevalence (%) Difference in prevalence
ANC surveillance Routine PMTCT Relative1 Absolute2
Region
South 5729 20.70 19.71 −4.8 −1.00
Center 8675 16.43 15.53 −5.5 −0.90
North 6159 8.22 7.81 −4.9 −0.41
Year
2007 10364 15.17 14.32 −5.6 −0.85
2009 10199 15.15 14.44 −4.7 −0.71
Total 20563 15.16 14.38 −5.1 −0.78
Notes:
1. relative difference between routine PMTCT HIV status (R) and ANC surveillance (S) calculated as (R-S)/S where R+/R- refers to routine PMTCT HIV status and S+/S- refers
to ANC surveillance HIV status.
2. absolute difference between routine PMTCT HIV status (R) and ANC surveillance (S) calculated as (R-S).
Table 4 Potential effect of missing routine PMTCT HIV status on estimated HIV prevalence in Mozambique
A. ANC surveillance HIV prevalence by routine PMTCT HIV test status
Total ANC test results by availability of PMTCT rapid test
Due to refusal Due to reasons other than refusal or known positive
PMTCT HIV status missing due to
refusal
PMTCT HIV status
not missing due to
refusal
PMTCT HIV status missing due to
other reasons
PMTCT HIV status not
missing due to other
reasons
HIV+ 3283 9 3274 94 3189
Total 21222 83 21139 511 20711
HIV
Prevalence
15.5% 10.8% (6.6-15.0) 15.5% (12.8-18.2) 18.4% (12.5-24.3) 15.4% (12.7-18.1)
B. Measures of effect of missing test results on HIV prevalence







Percent bias3 0.12% −0.47%
Prevalence ratio4 0.70 1.19
Notes:
1. Absolute difference is the HIV prevalence in those whose PMTCT HIV status is missing minus the HIV prevalence in those for whom it is present.
2. Relative difference is the absolute difference divided by the HIV prevalence among those for whom the PMTCT HIV status is present.
3. Percent bias is the HIV prevalence in those for whom PMTCT HIV status is present minus the overall HIV prevalence, divided by the overall HIV prevalence.
4. The prevalence ratio is the prevalence amongst those for whom the PMTCT HIV status is missing divided by the prevalence among those for whom the PMTCT
HIV status is not missing.
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designed to assess diagnostic performance rely on the
existence of a pre-existing reference standard to define
true positives and true negatives [6]. We found relatively
low levels of positive percent agreement for the PMTCT
HIV rapid test results in this study, given the high sensitiv-
ity and specificity of modern HIV tests regardless of
ELISA or rapid format. Based on published operational
characteristics of the tests used in this study, the expected
net sensitivity and specificity of both the rapid test and
ELISA algorithms are 100%. This inconsistency between
the positive percent agreement and the published oper-
ational characteristics of the tests implies that either the
ELISA or rapid tests are not performing as published or
test results are not being documented correctly. Future
studies would need to be undertaken to determine to what
degree these inconsistencies can be attributed to rapid
tests, ELISA tests, or documentation errors.
In spite of the low levels of agreement found in this
study, the impact on prevalence estimates among preg-
nant women was modest: HIV prevalence estimates based
on PMTCT rapid test results at ANC surveillance sites
would have been less than one percentage point lower
than those obtained from centralized ELISA testing, al-
though relative differences ranged from 0-22.2% at the site
level. The overall difference of less than one percentage
point among pregnant women in Mozambique would be
unlikely to trigger a change in national HIV policy.
However, as ANC estimates may be the most reliable HIV
prevalence data available in districts where sentinel sites
exist, site-level differences could influence local inter-
pretations of the status or course of the HIV epidemic.
The impact of differential refusal bias was also quite
limited: although the relative difference in HIV prevalence
was lower in refusers compared to non-refusers (10.8% vs.
15.5%), the low PMTCT test refusal rate of only 0.4%
means HIV estimates would only have been increased by
0.12 percentage points if results from those who refused
HIV testing during PMTCT were removed. Although
there were only 83 refusers in this study, there were an
additional 511 women who were missing rapid test results
but who did not have a documented refusal or history of a
positive HIV test. Interestingly, HIV prevalence in these
women was higher than those who were not missing
results for reasons other than refusal or known status
(18.4% vs. 15.4%). It is possible this group included women
whose known status was not reported or not correctly
recorded. However, had these women been excluded from
the ANC surveillance system prevalence would have only
decreased by 0.47 percentage points.
Given the near-universal uptake of both PMTCT
testing and ANC surveillance, participation biases are
not a primary concern for migrating to routine data
sources for ANC surveillance in Mozambique. However,
the poor positive percent agreement between rapid and
ELISA-based testing is concerning. There are various
possible explanations, including: 1) problems with test
manufacturing or storage, 2) problems with specimen stor-
age or handling, 3) non-compliance with recommended
rapid and/or ELISA testing procedures, such as not waiting
for the designated period before interpreting rapid test
results, 4) data entry or transcription errors during the
ANC visit or when entering surveillance data centrally, 5)
swapping of test results between specimens due to
unlinked anonymous testing or for other reasons, 6)
differing window periods which could lead to biological
false-negatives. Double entry of data and automatic tran-
scription of laboratory test results, and internal quality
assurance procedures for ELISA-based testing reduced the
likelihood of some, but not all types of errors. External
quality assurance has generally found low (≤1%) discrep-
ancy rates for ANC surveillance testing. The national HIV
external quality assessment program was established in
2006 by the National Institute of Health to monitor the
quality of diagnostic HIV rapid testing. The program
includes proficiency testing and included ANC nurses
from PMTCT programs at 11 of the 36 sentinel sites in
2007 and 13 of 36 sites in 2009.
The lack of a reference standard to assign the true
HIV status of each participant, along with our inability
to identify the relative contribution of each source to the
differences between PMTCT testing and ANC surveil-
lance are the primary limitations of this study. Nonethe-
less, these limitations do not diminish the value of being
able to identify these discrepancies, assess their impact
on HIV prevalence estimates at the aggregate and site
levels, and assess the potential impact of refusal bias on
prevalence estimates.
While this study focused on HIV prevalence estimates
among pregnant women at the national and regional
levels, ANC surveillance data are routinely used to
assess the impact of the Mozambican HIV epidemic
through mathematical models including Spectrum that
rely on site-level prevalence estimates, thus a sensitivity
analysis that assesses the impact of the use of routine
PMTCT data in these models should be performed
before recommending a switch to routine PMTCT test
data for surveillance purposes.
Although switching to PMTCT-based surveillance
would be premature in Mozambique, comparisons
between PMTCT and ANC surveillance results should
be repeated in the future to verify the potential improv-
ing trend in agreement seen from 2007-2009. A more
comprehensive evaluation of routine PMTCT HIV test
results should be conducted at ANC surveillance sites
in order to determine if data will be sufficiently available
and complete to allow their use for surveillance. Fur-
thermore, the national HIV external quality assessment
program should be expanded to cover service delivery
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points at all sites which may participate in a future sur-
veillance program based on routine HIV tests, including
all existing ANC sentinel surveillance sites. Sites which
reported PPA less than 90% should be evaluated closely
to determine, if possible, the underlying causes of poor
test result agreement. Establishing a comprehensive
quality management program at ANC surveillance sites
could further reduce discrepancies that are due to site-
level issues with HIV diagnostic testing.
Conclusions
The poor agreement across test results found in this study
implies that tests are not performing consistent with their
published operational characteristics and indicates it would
be premature to replace ANC surveillance with routine
PMTCT test data. However, the significant improvements
in agreement seen from 2007 to 2009, should they continue
in the future, are cause for optimism. In addition to
confirming this possible positive trend in agreement rates
and assessing the sensitivity of the Spectrum model to vari-
ation in site prevalence estimates, it will also be important
to evaluate the availability, quality and completeness of
HIV test results originating from routine ANC data systems
before recommending that these data be used to replace
data collected in ANC surveillance surveys.
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